Dechra

Safety Data Sheet

According to New Zealand, Hazardous Substances and New Organisms Act 1996 (HSNO Act) and Regulations, as amended.

Initial preparation date: 02.21.2019

Revision date: 02.23.2024 Page **1** of **11**

CEPHACIN Flavoured 200/600/1000 Tablets

SECTION 1: Identification

Product identifier

Product name: CEPHACIN Flavoured 200/600/1000 Tablets

Synonyms: Cephalexin Flavoured Tablets

Additional information: None

Recommended use of the product and restriction on use:

Relevant identified uses: VETERINARY USE: Antibiotic

Uses advised against: Not for human use.

Reasons why uses advised against: Veterinary product.

Manufacturer or supplier details

Supplier:

Dechra Veterinary Products NZ Limited

PO Box 1604,

Paraparaumu Beach, 5252

New Zealand

Phone: 0800 479 838 Email: info.nz@dechra.com

Website: http://www.dechra.co.nz/

Emergency telephone number:

National Poisons Centre, New Zealand

0800 764 766

SECTION 2: Hazards identification

Not Classified as a Dangerous Good according to NZS 5433:2012 Transport of Dangerous Goods on Land.

Classified in accordance with the relevant criteria of the HSNO Act 1996, the Hazardous Substances (Classification) Notice 2017 and the Hazardous Substances (Minimum Degrees of Hazard) Notice 2017, New Zealand.

HSNO Classification or Subclasses – Physical hazards: Not applicable

HSNO Classification or Subclasses – Health hazards:

Class	GHS Category	HSNO Category
Skin irritation	Category 2	6.3A
Eye irritation	Category 2	6.4A
Respiratory sensitization	Category 1	6.5A
Skin sensitization	Category 1	6.5B

HSNO Classification or Subclasses – Environmental hazards: Not applicable

GHS classification:

Skin irritation, category 2 Eye irritation, category 2

Respiratory sensitization, category 1

Skin sensitization, category 1

According to New Zealand, Hazardous Substances and New Organisms Act 1996 (HSNO Act) and Regulations, as amended.

Initial preparation date: 02.21.2019 Page 2 of 11

Revision date: 02.23.2024

CEPHACIN Flavoured 200/600/1000 Tablets

Label elements

Hazard pictogram(s):





Signal word: Danger

Hazard statements:

H315 Causes skin irritation

H319 Causes serious eye irritation

H334 May cause allergy or asthma symptoms or breathing difficulties if inhaled

H317 May cause an allergic skin reaction

Precautionary statements:

P102 Keep out of reach of children.

P261 Avoid breathing dust.

P264 Wash skin thoroughly for 15 minutes after handling.

P272 Contaminated work clothing should not be allowed out of the workplace.

P280 Wear protective gloves, protective clothing and eye protection.

 ${\bf P284}\ In\ case\ of\ inadequate\ ventilation\ wear\ respiratory\ protection.}$

P302+P352 IF ON SKIN: Wash with plenty of soap and water.

P321 Specific treatment (see supplemental first aid instructions on this label).

P333+P313 If skin irritation or rash occurs: Get medical advice/attention.

P362+P364 Take off contaminated clothing and wash before reuse.

P305+P351+P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.

P337+P313 If eye irritation persists: Get medical advice/attention.

P304+P341 IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.

P342+P311 If experiencing respiratory symptoms: Call a POISON CENTER or doctor.

P501 Dispose of contents and container in accordance with local, regional, national, and international regulations.

Hazards not otherwise classified:

None.

SECTION 3: Composition/information on ingredients

Identification	Name	Weight %
CAS number: 23325-78-2	Cephalexin monohydrate	65
CAS number: 9004-34-6	Microcrystalline cellulose	10-20
CAS number: 7789-77-7	Calcium phosphate	10-20

According to New Zealand, Hazardous Substances and New Organisms Act 1996 (HSNO Act) and Regulations, as amended.

Initial preparation date: 02.21.2019 Page **3** of **11**

Revision date: 02.23.2024

CEPHACIN Flavoured 200/600/1000 Tablets

Identification	Name	Weight %
CAS number: NA	Artificial beef flavor	5-10
CAS number: 557-04-0	Magnesium stearate	1-3

Additional information:

The specific chemical identity and/or exact percentage (concentration) of composition has been withheld as a trade secret under the provisions of Sections 55 (7) of the HSNO Act.

SECTION 4: First-aid measures

For advice, contact a Poisons Information Center (e.g. phone Australia 131 126, New Zealand 0800 764 766) or a doctor.

Description of first aid measures

General notes:

Show this Safety Data Sheet to the doctor in attendance.

After inhalation:

If inhaled, remove person to fresh air and place in a position comfortable for breathing. Keep person at rest. If breathing is difficult, administer oxygen. If breathing has stopped, provide artificial respiration. If experiencing respiratory symptoms, seek medical advice/attention.

After skin contact:

Remove contaminated clothing and shoes. Rinse skin with copious amounts of water [shower] for several minutes. Launder contaminated clothing before reuse. If symptoms develop or persist, seek medical advice/attention.

After eve contact:

Immediately rinse eyes with plenty of water, occasionally lifting the upper and lower eyelids. Check for and remove any contact lenses. Continue to rinse for at least 15 minutes. If eye irritation develops or persists, seek medical advice/attention.

After swallowing:

If swallowed, DO NOT induce vomiting unless told to do so by a physician or poison control center. Rinse mouth with water. Never give anything by mouth to an unconscious person. If spontaneous vomiting occurs, place on the left side with head down to prevent aspiration of liquid into the lungs. If symptoms develop or persist, seek medical advice/attention.

Most important symptoms and effects, both acute and delayed:

Acute symptoms and effects:

Dermal exposure may cause irritation and/or an allergic skin reaction. Symptoms include redness, pain, burning, inflammation, itching, rash and dermatitis.

Eye contact may result in irritation, redness, pain, inflammation, itching, burning and tearing. Inhalation exposure may cause allergy, asthma symptoms or breathing difficulties. Symptoms may include cough, chronic phlegm, shortness of breath, wheezing and chest tightness. Symptoms may be delayed.

Delayed symptoms and effects:

Effects are dependent on exposure (dose, concentration, contact time).

According to New Zealand, Hazardous Substances and New Organisms Act 1996 (HSNO Act) and Regulations, as amended.

Initial preparation date: 02.21.2019 Page 4 of 11

Revision date: 02.23.2024

CEPHACIN Flavoured 200/600/1000 Tablets

Immediate medical attention and special treatment:

Specific treatment:

Treatment for any adverse effects should be symptomatic. Cephalexin is widely distributed in body fluids and tissues including pleural, pericardial, peritoneal and synovial fluid. It also crosses the placenta. The blood brain barrier is only significantly crossed in the presence of inflammation.

Notes for the doctor:

Treat symptomatically.

Workplace Facilities:

No additional information.

SECTION 5: Fire-fighting measures

Extinguishing media

Suitable extinguishing media:

Use an extinguishing agent suitable for the surrounding fire.

Unsuitable extinguishing media:

Do not use water jet.

Specific hazards during fire-fighting:

Non flammable. May evolve carbon oxides, Sulphur oxides, nitrogen oxides and hydrocarbons when heated to decomposition.

Special protective equipment for firefighters:

Fire-fighters should wear appropriate protective equipment and self-contained breathing apparatus (SCBA) with a full-face piece operated in positive pressure mode.

Special precautions:

Avoid contact with skin, eyes, hair and clothing. Do not breathe fumes/gas/mists/aerosols/vapors/dusts. Move containers from fire area if safe to do so. Use water spray/fog for cooling fire exposed containers. Avoid unnecessary run-off of extinguishing media which may cause pollution.

Hazchem or Emergency Action Code:

Not Applicable.

SECTION 6: Accidental release measures

Personal precautions, protective equipment and emergency procedures:

Wear recommended personal protective equipment (see Section 8). Avoid contact with skin, eyes and clothing. Wash thoroughly after handling.

Environmental precautions:

Prevent further leakage or spillage if safe to do so. Prevent from reaching drains, sewers and waterways. Discharge into the environment must be avoided.

Methods and material for containment and cleaning up:

Contain and collect spillage and place in suitable container for future disposal. Dispose of in accordance with all applicable regulations (see Section 13).

Reference to other sections:

For personal protective equipment see Section 8. For disposal see Section 13.

According to New Zealand, Hazardous Substances and New Organisms Act 1996 (HSNO Act) and Regulations, as amended.

Initial preparation date: 02.21.2019 Page **5** of **11**

Revision date: 02.23.2024

CEPHACIN Flavoured 200/600/1000 Tablets

SECTION 7: Handling and storage precautions

Precautions for safe handling:

Use appropriate personal protective equipment (see Section 8). Use only with adequate ventilation. Avoid breathing mist/vapour/spray/dust. Do not eat, drink, smoke, or use personal products when handling chemical substances. Avoid contact with skin, eyes and clothing. Wash affected areas thoroughly after handling. Keep away from incompatible materials (See Section 10). Keep containers tightly closed when not in use.

Conditions for safe storage, including any incompatibilities:

Store in cool, dry, well-ventilated location out of direct sunlight. Keep away from food and beverages. Protect from freezing and physical damage. Store away from heat, open flames and other sources of ignition. Keep container tightly sealed. Store away from incompatible materials (See Section 10).

Store below 30°C (room temperature). Protect from light.

Safe packaging material

Suitable material:

Not determined or not applicable.

Unsuitable material:

Not determined or not applicable.

SECTION 8: Exposure controls and personal protection

Occupational Exposure limit values:

Country (Legal Basis)	Substance	Identifier	Permissible concentration
New Zealand	Microcrystalline cellulose	9004-34-6	8-Hour TWA: 10 mg/m ³
	Magnesium stearate	557-04-0	8-Hour TWA: 10 mg/m³ (as Stearates)

Biological limit value:

No biological exposure limits noted for the ingredient(s).

Information on monitoring procedures:

Not determined or not applicable

Appropriate engineering controls:

Emergency eye wash stations and safety showers should be available in the immediate vicinity of use or handling. Provide adequate ventilation to maintain the airborne concentrations of vapor, mists, and/or dusts below the applicable workplace exposure limits, while observing recognized national standards (or equivalent).

Personal protection equipment

Eye and face protection:

Safety glasses or goggles. Use eye protection equipment that has been tested and approved by recognized national standards (or equivalent).

Skin and body protection:

Chemical resistant, impervious gloves approved by the appropriate standards. Gloves must be inspected prior to use. Avoid skin contact with used gloves. Appropriate techniques should be used to remove used gloves and contaminated clothing. Personal protective equipment for the body should be selected based on the task being performed and the risks involved and should be approved by a specialist before handling this product. Ensure that all personal protective equipment is approved by recognized national standards (or equivalent).

According to New Zealand, Hazardous Substances and New Organisms Act 1996 (HSNO Act) and Regulations, as amended.

Initial preparation date: 02.21.2019 Page 6 of 11

Revision date: 02.23.2024

CEPHACIN Flavoured 200/600/1000 Tablets

Respiratory protection:

If engineering controls do not maintain airborne concentrations below the applicable workplace exposure limits, or to an acceptable level (if exposure limits have not been established), a respirator approved by recognized national standards (or equivalent) must be worn.

General hygienic measures:

When handling chemical products, do not eat, drink or smoke. Wash hands after handling, before breaks, and at the end of the workday. Avoid contact with skin, eyes and clothing. Wash contaminated clothing before reuse. Perform routine housekeeping.

SECTION 9: Physical and chemical properties

Appearance	Solid. Round off-white tablets
Colour	Off-white
Odour	Meat odour
Odour threshold	Not determined or not available.
рН	Not determined or not available.
Melting point/freezing point	Not determined or not available.
Initial boiling point/range	Not determined or not available.
Flash point (closed cup)	Not determined or not available.
Flammability (solid, gas)	Non-flammable
Upper flammability/explosive limit	Not determined or not available.
Lower flammability/explosive limit	Not determined or not available.
Vapour pressure	Not determined or not available.
Vapour density	Not determined or not available.
Relative density	Not determined or not available.
Solubilities	Not determined or not available.
Partition coefficient (n-octanol/water)	Not determined or not available.
Auto/Self-ignition temperature	Not determined or not available.
Decomposition temperature	Not determined or not available.
Dynamic viscosity	Not determined or not available.
Kinematic viscosity	Not determined or not available.
Particle characteristics	Not determined or not available.

Other information: No additional information.

SECTION 10: Stability and reactivity

Reactivity:

Not reactive under recommended handling and storage conditions.

Chemical stability:

Stable under recommended handling and storage conditions.

Possibility of hazardous reactions:

Hazardous reactions are not anticipated under recommended conditions of handling and storage.

According to New Zealand, Hazardous Substances and New Organisms Act 1996 (HSNO Act) and Regulations, as amended.

Initial preparation date: 02.21.2019 Page **7** of **11**

Revision date: 02.23.2024

CEPHACIN Flavoured 200/600/1000 Tablets

Conditions to avoid:

Extreme heat, open flames, hot surfaces, sparks, ignition sources, moisture and incompatible materials.

Incompatible materials:

Incompatible with oxidising agents (e.g. hypochlorites).

Hazardous decomposition products:

May evolve carbon oxides and hydrocarbons when heated to decomposition.

SECTION 11: Toxicological information

Acute toxicity:

Assessment: Based on available data, the classification criteria are not met.

Product data: No data available.

Substance data:

Name	Route	Result
Cephalexin monohydrate	oral	LD50 Mouse: 1600 mg/kg
Microcrystalline cellulose	dermal	LD50 Rabbit: > 2000 mg/kg
	inhalation	LC50 Rat: > 5.8 mg/L(4hr[dust/mist])
	oral	LD50 Rat: > 5000 mg/kg
Magnesium stearate	dermal	LD50 Rat: >2000 mg/kg

Skin corrosion/irritation

Assessment: Causes skin irritation **Product data:** No data available.

Substance data:

Name	Result
Calcium phosphate	Causes skin irritation.

Serious eye damage/irritation:

Assessment: Causes serious eye irritation.

Product data: No data available.

Substance data:

Name	Result
Calcium phosphate	Causes serious eye irritation.

Respiratory or skin sensitization:

Assessment:

May cause allergy or asthma symptoms or breathing difficulties if inhaled.

May cause an allergic skin reaction.

Product data: No data available. **Substance data:** No data available.

Name	Result
Cephalexin Monohydrate	May cause an allergic skin reaction.
	May cause allergy or asthma symptoms or breathing difficulties if
	inhaled.

According to New Zealand, Hazardous Substances and New Organisms Act 1996 (HSNO Act) and Regulations, as amended.

Initial preparation date: 02.21.2019 Page **8** of **11**

Revision date: 02.23.2024

CEPHACIN Flavoured 200/600/1000 Tablets

Carcinogenicity

Assessment: Based on available data, the classification criteria are not met.

Product data: No data available. **Substance data:** No data available.

International Agency for Research on Cancer (IARC): None of the ingredients are listed.

Germ cell mutagenicity

Assessment: Based on available data, the classification criteria are not met.

Product data: No data available.

Substance data: No data available.

Reproductive toxicity

Assessment: Based on available data, the classification criteria are not met.

Product data: No data available. **Substance data:** No data available.

Specific target organ toxicity (single exposure)

Assessment: Based on available data, the classification criteria are not met.

Product data: No data available.

Substance data:

Name	Result
Calcium phosphate	May cause respiratory irritation.

Specific target organ toxicity (repeated exposure)

Assessment: Based on available data, the classification criteria are not met.

Product data: No data available. **Substance data:** No data available.

Aspiration toxicity

Assessment: Based on available data, the classification criteria are not met.

Product data: No data available. **Substance data:** No data available.

Information on likely routes of exposure:

Skin contact, Eye contact, Inhalation

Symptoms related to the physical, chemical and toxicological characteristics:

See section 4 of this SDS.

Other information:

No data available.

SECTION 12: Ecological information

Acute (short-term) toxicity

Assessment: Based on available data, the classification criteria are not met.

Product data: No data available. **Substance data:** No data available.

According to New Zealand, Hazardous Substances and New Organisms Act 1996 (HSNO Act) and Regulations, as amended.

Initial preparation date: 02.21.2019 Page **9** of **11**

Revision date: 02.23.2024

CEPHACIN Flavoured 200/600/1000 Tablets

Chronic (long-term) toxicity

Assessment: Based on available data, the classification criteria are not met.

Product data: No data available.
Substance data: No data available
Persistence and degradability
Product data: No data available.
Substance data: No data available.

Bioaccumulative potential

Product data: No data available. **Substance data:** No data available.

Mobility in soil

Product data: No data available. **Substance data:** No data available.

Hazard to the ozone layer

Product data: No data available.

Substance data: No data available.

Other adverse effects: No data available.

SECTION 13: Disposal considerations

Disposal methods:

It is the responsibility of the waste generator to properly characterize all waste materials according to applicable regulatory agencies. Dispose of in accordance with all applicable local, regional, state and federal regulations.

Contaminated packages:

Not determined or not applicable.

Disposal methods that should not be used:

No additional information.

SECTION 14: Transportation information

Road/Rail transport: (NZS 5433:1999)

UN number	Not regulated
UN proper shipping name	Not regulated
UN transport hazard class(es)	None
Packing group	None
Environmental hazards	None
Special precautions for user	None

According to New Zealand, Hazardous Substances and New Organisms Act 1996 (HSNO Act) and Regulations, as amended.

Initial preparation date: 02.21.2019 Page **10** of **11**

Revision date: 02.23.2024

CEPHACIN Flavoured 200/600/1000 Tablets

International Air Transport Association Dangerous Goods Regulations (IATA-ICAO)

UN number	Not regulated
UN proper shipping name	Not regulated
UN transport hazard class(es)	None
Packing group	None
Environmental hazards	None
Special precautions for user	None

International Maritime Dangerous Goods (IMDG)

UN number	Not regulated
UN proper shipping name	Not regulated
UN transport hazard class(es)	None
Packing group	None
Environmental hazards	None
Special precautions for user	None

Transport in bulk according to Annex II of MARPOL and the IBC Code: Not Applicable

SECTION 15: Regulatory information

New Zealand Inventory of Chemicals (NZIoC): All Ingredients are listed.

HSNO Classification or Subclasses:

Class	GHS Category	HSNO Category
Skin irritation	Category 2	6.3A
Eye irritation	Category 2	6.4A
Respiratory sensitization	Category 1	6.5A
Skin sensitization	Category 1	6.5B

HSNO Group Standard Name:	HSNO Approval Number:
Veterinary Medicines (Limited Pack Size, Finished	HSR100757
Dose) Group Standard 2017	

HSNO Controls: Not determined.

Approved handler test certificate: Not determined.

Tracking: Not determined.

Controlled substance license requirements: Not applicable.

Agricultural Compounds and Veterinary Medicines Act 1997:

ACVM Number	A011577 (200mg), A011216 (600mg), A011579
	(1000mg)

Montreal Protocol (Ozone Depleting Substances): None of the ingredients are listed.

Stockholm Convention (Persistent Organic Pollutants): None of the ingredients are listed.

Rotterdam Convention (Prior Informed Consent): None of the ingredients are listed.

Basel Convention (Hazardous Waste): None of the ingredients are listed.

According to New Zealand, Hazardous Substances and New Organisms Act 1996 (HSNO Act) and Regulations, as amended.

Initial preparation date: 02.21.2019 Page 11 of 11

Revision date: 02.23.2024

CEPHACIN Flavoured 200/600/1000 Tablets

SECTION 16: Other information

Abbreviations and Acronyms:

	•
ATE	Acute Toxicity Estimate
BCF	Bioconcentration Factor
CAS	Chemical Abstracts Service
EC50	Effective Concentration of 50%
GHS	Globally Harmonized System
HSNO	Hazardous Substances and New Organisms
IARC	International Agency for Research on Cancer
IATA	International Air Transport Association
IBC	Intermediate Bulk Container
ICAO	International Civil Aviation Organization
IMDG	International Maritime Dangerous Goods
LC50	Lethal Concentration 50%
LD50	Lethal Dose 50%
MARPOL	International Convention for the Prevention of Pollution from Ships
NZIoC	New Zealand Inventory of Chemicals
TWA	Time Weighted Average
UN	United Nations
VOC	Volatile Organic Compounds

Disclaimer:

The information provided in this SDS is correct, to the best of our knowledge, based on information available. The information given is designed only as a guidance for safe handling, use, storage, transportation and disposal and is not to be considered a warranty or quality specification. The information relates only to the specific material designated and may not be valid for such material used in combination with any other materials, unless specified in the text. The responsibility to provide a safe workplace remains with the user.

Initial preparation date: 02.21.2019

Revision date: 02.23.2024

Revision Notes:

Revision date	Notes
02-23-2024	Version 2; Supercedes Version 1 dated 2019-02-21

End of Safety Data Sheet